Five teams have been funded in the context of the partnership between Quebec, Canada, and France. Some are working on the role of prions, a protein, in diseases of the brain. It's based in Vancouver, with some people in Quebec and some people in France. Then there are other animal models.
That's quite useful, because again, there's a bit of sharing of approaches and technology. And these grants are fairly large. They are bigger. They are in the $2 million category.
With Germany and the United Kingdom, the process is just under way. Now we are trying to establish the priority--which subfield of Alzheimer's disease we should fund--in partnership. It will again be in support of a joint platform.
Serge was talking about brain imaging as a potential marker. Well, if you take your image in London, England, and you take your image in Montreal, how do you compare? It's easy to take the image. The issue is analyzing it with different machines. Basically, standardizing all these methodologies in terms of diagnosis and in terms of biomarkers is very important. That's why international partnerships are so important.
The next one developing is with China and with the States.